90% of Surveyed Companies Have Dedicated a Team of Health Economics and Outcomes Research Specialists

RESEARCH TRIANGLE PARK, NC--(Marketwired - July 11, 2016) - Among surveyed pharmaceutical companies, approximately 90% now have dedicated teams of health economics and outcomes research (HEOR) specialists at both global and country levels. Global teams can provide significant assistance to country-level groups with big picture data and broad strategy elements that can be adjusted to meet individual payer needs.

When it comes to meeting those payer needs from a health economics perspective, pharmaceutical companies are under increasing pressure to provide a full value story to payers that addresses patient outcomes, pharmacoeconomic and even budgetary questions. A centralized HEOR specialist team can provide companies with a number of advantages, according to primary intelligence provider Cutting Edge Information.

"Health economics and outcomes research teams must be well staffed to handle a wide range of responsibilities," said Jacob Presson, data product team leader at Cutting Edge Information. "Typical HEOR teams staff four types of employees; senior management, HEOR analysts, health outcomes liaisons (HOLs), and administrative FTEs."

The survey analysis can be found in Cutting Edge Information's study, Building World-Class HEOR Teams: Creating Convincing Value Proposition for Payers. The study serves as a how-to guide for not only structuring health economics operations at the global and country levels, but also for allocating pharmacoeconomic resources and developing HEOR strategy. The report includes data and best practices that address how frontline HEOR teams focus on working directly with payers while receiving adequate support by global pharmacoeconomic groups.

Building World-Class HEOR Teams: Creating Convincing Value Proposition for Payers, available at http://www.cuttingedgeinfo.com/research/market-access/health-economics-and-outcomes-research/, highlights HEOR group structure, staffing and spending at pharmaceutical and medical device companies around the world. The report's resource metrics allow health economics groups to benchmark their activities against the rest of the industry and to ensure that they are effectively supporting their products. Highlights include:

• Benchmarks showing HEOR spending from 2013 to 2015 per company and on a per-product basis.
• Data showing HEOR group oversight, leadership and funding sources.
• Executive perspectives on demonstrating the value of HEOR internally.
• Insights on how to ensure that stakeholders beyond payers are understood when developing health economics research.

For other market access topics, view Cutting Edge Information's market access library at http://www.cuttingedgeinfo.com/library/market-access/.

Image Available: http://www.marketwire.com/library/MwGo/2016/7/8/11G105806/Images/July_11_-_PH211_-_90_Percent_have_HEOR_Dedicated_T-cf1f27b7b6e5988086d55b1d349b9d7a.jpg